Form: 8-K

Current report filing

June 28, 2006


SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


FORM 8-K

 


CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES AND EXCHANGE ACT OF 1934

Date of report (date of earliest event reported): June 26, 2006

 


COMMONWEALTH BIOTECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 


 

Virginia   001-13467   56-1641133

(State or Other Jurisdiction

of Incorporation

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

601 Biotech Drive

Richmond, Virginia 23235

(Address of principal executive offices)

Registrant’s telephone number, including area code: (804) 648-3820

 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



ITEM 8.01 OTHER EVENTS

On June 26, 2006, Commonwealth Biotechnologies, Inc. (the “Company”) issued a press release announcing that one of its directors, Samuel Sears, Jr., intends to sell 32,000 shares of his stock in the Company. Mr. Sears continues to serve on the Board of the Company and will retain a significant number of shares of the Company’s stock.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

 

(a) Financial statements of businesses acquired.

Not Applicable.

 

(b) Pro forma financial information.

Not Applicable.

 

(c) Shell company transactions.

Not Applicable.

 

(d) Exhibits.

 

99.1    Press release, dated June 26, 2006, relating to the sale of 32,000 shares of stock in Commonwealth Biotechnologies, Inc. by Samuel Sears, Jr.

 

2


Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

COMMONWEALTH BIOTECHNOLOGIES, INC.
By:  

/s/ Robert B. Harris, Ph.D.

  Robert B. Harris, Ph.D.
  President and Chief Executive Officer

Dated: June 28, 2006

 

3


EXHIBIT INDEX

 

Number  

Description of Exhibit

99.1   Press release, dated June 26, 2006, relating to the sale of 32,000 shares of stock in Commonwealth Biotechnologies, Inc. by Samuel Sears, Jr.

 

4